FDA Tweaks Drug Codes for Easier Barcode Scans
Published Date: 3/5/2026
Rule
Summary
The FDA is updating the National Drug Code (NDC) to a clear, 12-digit format with three parts to make drug labeling easier to read and track. They’re also allowing new types of barcodes on drug packages that meet these rules. This change affects drug makers and sellers and kicks in on March 7, 2033, giving everyone plenty of time to get ready without extra costs.
Analyzed Economic Effects
8 provisions identified: 6 benefits, 2 costs, 0 mixed.
All FDA NDCs Must Be 12 Digits
FDA requires every FDA-assigned National Drug Code (NDC) to be 12 digits in a 6-4-2 format (6-digit labeler, 4-digit product, 2-digit package). This requirement takes effect March 7, 2033 and applies to existing 10-digit NDCs, which must be converted to the 12-digit format.
Industry Cost Estimate Provided
FDA estimates annualized industry costs to convert to the uniform 12-digit NDC format at about $14.64 million (range $7.64M to $22.79M) using a 7% discount rate, and about $14.90 million (range $7.79M to $23.18M) using a 3% discount rate, over a 10-year horizon.
Standardization Aims to Reduce Medication Errors
FDA says a single, uniform 12-digit NDC format should reduce errors from converting between multiple NDC formats and lower the need for extra quality control by payors and prescribers. FDA also notes the rule should help avoid potential public-health risks from medication confusion.
7-Year Delay Before Rule Starts
FDA set the rule's effective date 7 years after publication, so the 12-digit NDC requirement starts on March 7, 2033. FDA states it will use that 7-year period to engage with and help industries prepare for the change.
3-Year Post-Effective Label Transition
After the March 7, 2033 effective date, FDA allows a 3-year transition period during which it does not intend to object to continued use of pre-existing 10-digit NDCs on drug labeling for products remaining in interstate commerce. During this transition, firms should make systems that can handle both 10-digit and 12-digit formats.
Barcode Options Expanded for Labels
FDA will allow either linear or nonlinear barcodes on drug labels as long as the barcode format conforms to the rule's standards and is recognized by FDA. This gives manufacturers flexibility in choosing barcodes that meet the new requirements.
FDA Will Publish 10-to-12 Digit Mapping
FDA intends to publish a database that maps each existing 10-digit NDC to its corresponding 12-digit NDC and will keep that mapping available at least until the end of the transition period. This mapping aims to reduce conversion errors during implementation.
Converted NDCs Aren't 'New' NDCs
FDA states converting a pre-effective-date 10-digit NDC into the 12-digit format is a ministerial administrative change and is not considered assignment of a "new" NDC for registration, listing, or user-fee purposes. A drug gets a truly new NDC only if FDA assigns a new NDC after the effective date because of a product change described in regulation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-04365, National Standards for Traffic Control Devices; the Manual on Uniform Traffic Control Devices for Streets and Highways; Revision
The Federal Highway Administration just updated the national rulebook for traffic signs and signals, called the MUTCD, fixing small errors and making things clearer for everyone on public roads. This update affects all drivers, bikers, and road workers by helping keep roads safer and easier to navigate. The new rules kick in on March 5, 2026, with no big costs, just smoother, smarter traffic control everywhere.
Next: 2026-04373, Rules Regarding Delegation of Authority; Correction
The Federal Reserve fixed and updated its rules about who can make certain decisions on its behalf. This change adds some previously approved delegations and corrects small errors to keep things running smoothly. It affects Board members, staff, and Reserve Banks and takes effect immediately on March 5, 2026, with no new costs involved.